 Hypoglycemic Agents
"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 2 | 3 | | 1998 | 0 | 1 | 1 | | 1999 | 3 | 2 | 5 | | 2000 | 3 | 1 | 4 | | 2001 | 1 | 2 | 3 | | 2002 | 2 | 2 | 4 | | 2003 | 7 | 1 | 8 | | 2004 | 5 | 6 | 11 | | 2005 | 3 | 11 | 14 | | 2006 | 3 | 6 | 9 | | 2007 | 10 | 11 | 21 | | 2008 | 11 | 8 | 19 | | 2009 | 15 | 17 | 32 | | 2010 | 17 | 8 | 25 | | 2011 | 14 | 11 | 25 | | 2012 | 21 | 5 | 26 | | 2013 | 16 | 15 | 31 | | 2014 | 25 | 12 | 37 | | 2015 | 22 | 9 | 31 | | 2016 | 23 | 11 | 34 | | 2017 | 29 | 20 | 49 | | 2018 | 37 | 20 | 57 | | 2019 | 29 | 15 | 44 | | 2020 | 23 | 40 | 63 | | 2021 | 13 | 36 | 49 | | 2022 | 7 | 49 | 56 | | 2023 | 5 | 33 | 38 | | 2024 | 42 | 35 | 77 | | 2025 | 43 | 8 | 51 |
To return to the timeline, click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Cherney DZI, Belmar N, Bjornstad P, Chacko MM, Gunnarsson TP, Hodgin JB, Kretzler M, Pruijm M, Schytz PA, Tuttle KR. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2025 Oct 30; 40(11):2182-2192.
-
Knowler WC, Pan Q, Shu S, Tripputi MT, Dabelea D, Edelstein SL, Kahn SE, Kuo S, Luchsinger JA, Shah V, Wallia A, Temprosa M. Analysis of Long-term Follow-up of a Randomized Clinical Trial With Departures From Assigned Treatments: Estimation of Metformin Effects on Diabetes and Its Complications in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2025 Oct 01; 48(10):1668-1675.
-
Turner LV, Sherr JL, Zaharieva DP, Baran J, Hirsch IB, Bode BW, Brown SA, Bzdick S, Church MM, Hansen DW, Kingman R, Laffel LM, Shah VN, Stone S, Vienneau TE, Huyett LM, Dumais B, Ly TT, Riddell MC. Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled Trial. Diabetes Care. 2025 Sep 01; 48(9):1598-1606.
-
Bramante CT, Stewart TG, Boulware DR, McCarthy MW, Gao Y, Rothman RL, Mourad A, Thicklin F, Cohen JB, Garcia Del Sol IT, Ruiz-Unger J, Shah NS, Mehta M, Cardona OQ, Scott J, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, Collins S, Dunsmore SE, Adam SJ, Lindsell CJ, Hernandez AF, Naggie S. Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA Intern Med. 2025 Sep 01; 185(9):1092-1101.
-
Presley CA, Butera NM, Krause-Steinrauf H, Desouza CV, Hollander PA, Hoogendoorn CJ, Lagari VS, Legowski EA, Martin CL, Rasouli N, Gonzalez JS, Cherrington AL. Lack of Association of Emotional Distress With Insulin Initiation in the GRADE Randomized Diabetes Comparative Effectiveness Trial. Sci Diabetes Self Manag Care. 2025 Aug; 51(4):382-393.
-
Sarwal A, Singh R, Wei G, Shen J, Nevers M, Hartsell SE, Derington CG, Takyi A, Chakravartula AR, Katkam N, Boucher RE, Drakos SG, Greene T, Beddhu S. Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes. Diabetes Obes Metab. 2025 Oct; 27(10):5865-5877.
-
Canonico ME, Hsia J, Masoudi FA, Bosworth HB, Greene S, Batch BC, Hamilton N, de Araujo TB, Jackson M, Broussard M, Gooden Z, Guthrie NL, Hansell B, Matteliano-Madu L, Mosesso K, Berman MA, Bonaca MP. Digital Therapeutic Based Randomized Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy: Rationale, Design, and Baseline Characteristics of the BRIGHT Trial. J Am Heart Assoc. 2025 Aug 05; 14(15):e038737.
-
Jacobs PG, Levy CJ, Brown SA, Riddell MC, Cinar A, Boughton CK, Breton MD, Dassau E, Forlenza G, Henderson RJ, Hovorka R, Maahs DM, Munshi M, Murphy H, Polsky S, Pratley R, Putman MS, Shah VN, Wilson LM, Zisser H, Ekhlaspour L. Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems. J Diabetes Sci Technol. 2025 Jul; 19(4):937-949.
-
Bergenstal RM, Heller A, Breton MD, Vigersky R, Brown SA, Forlenza GP, Sherr JL, Hovorka R, Russell SJ, Damiano ER, Putman MS, Beck RW, Renard E, Lal R, Cobelli C, Dassau E, Akturk HK, Weiss MA, Skyler JS. Evolution of the Artificial Pancreas: Components and Integration-CGMs, Insulin, and AP Systems. J Diabetes Sci Technol. 2025 Jul; 19(4):883-894.
-
Akturk HK, Brown SA, Beck RW, Sherr JL, Bergenstal RM, Kovatchev BP, Vigersky R, Breton MD, Hovorka R, Klonoff DC, Garg SK. Registration and Real-Life Studies on Automated Insulin Delivery Systems. Diabetes Technol Ther. 2025 Jul; 27(S3):S48-S59.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|